Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Cash from Financing Activities (2023 - 2025)

Historic Cash from Financing Activities for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to $5.9 million.

  • NewAmsterdam Pharma's Cash from Financing Activities rose 1005862.07% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $472.4 million, marking a year-over-year increase of 13285.18%. This contributed to the annual value of $659.5 million for FY2024, which is 730021.32% up from last year.
  • As of Q3 2025, NewAmsterdam Pharma's Cash from Financing Activities stood at $5.9 million, which was up 1005862.07% from $3.4 million recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma's Cash from Financing Activities ranged from a high of $456.6 million in Q4 2024 and a low of $58000.0 during Q3 2024
  • For the 3-year period, NewAmsterdam Pharma's Cash from Financing Activities averaged around $68.4 million, with its median value being $5.3 million (2024).
  • Over the last 5 years, NewAmsterdam Pharma's Cash from Financing Activities had its largest YoY gain of 1005862.07% in 2025, and its largest YoY loss of 9671.06% in 2025.
  • Quarter analysis of 3 years shows NewAmsterdam Pharma's Cash from Financing Activities stood at $186000.0 in 2023, then skyrocketed by 245389.78% to $456.6 million in 2024, then plummeted by 98.71% to $5.9 million in 2025.
  • Its last three reported values are $5.9 million in Q3 2025, $3.4 million for Q2 2025, and $6.5 million during Q1 2025.